In a significant transformation for the business-to-business (B2B) media landscape, Cleveland-based WTWH Media—the parent organization behind Drug Discovery & Development and dozens of other industry-leading publications—officially announced its transition to a new corporate identity: Arrowfly.
The announcement, made on July 13, 2026, marks more than just a name change; it represents a strategic pivot designed to align the company’s corporate persona with its expanded portfolio and vision for the future of professional intelligence. While the parent company has adopted the Arrowfly moniker, the operational integrity of its individual brands remains untouched. Drug Discovery & Development will continue to operate under its existing masthead, maintaining its editorial staff, archives, newsletter subscriptions, and digital presence without interruption.
The Evolution of a B2B Powerhouse
To understand the shift to Arrowfly, one must look at the meteoric rise of the organization formerly known as WTWH Media. Founded on the principle of high-quality, industry-specific journalism, the company has spent years curating a vast ecosystem of media assets.
Today, the company operates an impressive portfolio of over 40 B2B media brands and facilitates more than 45 industry-leading events. This footprint is strategically organized into three core networks:
- Engineering: Serving the technical backbone of modern industry.
- Healthcare and Life Sciences: Providing critical insights into drug discovery, medical devices, and health systems.
- Food, Retail, and Hospitality: Navigating the complexities of consumer-facing sectors.
Drug Discovery & Development remains a jewel in the crown of the Healthcare and Life Sciences network. It operates in close proximity to other influential brands within the group that serve the medical device sector, behavioral health, and senior care, creating a synergistic environment where cross-disciplinary expertise thrives.
Chronology of Transformation: From Growth to Rebranding
The transition to Arrowfly is the culmination of a multi-year growth trajectory that saw the company transition from a niche publisher to a diversified media powerhouse.
- The Foundation (Pre-2022): The company established its reputation through deep-dive editorial authority, focusing on engineering and life sciences, sectors where accuracy and nuance are paramount.
- The Strategic Inflection Point (2022): A landmark partnership with Mountaingate Capital provided the necessary capital and strategic guidance to accelerate the company’s expansion. This investment allowed for a series of aggressive acquisitions, broadening the company’s reach into specialized areas of the life sciences and healthcare sectors.
- Leadership Transition (2025): The arrival of Matt Logan as CEO marked a new chapter for the firm. With over 25 years of experience in the B2B media sector, Logan was tasked with streamlining the company’s operations and preparing it for a modern, digital-first future.
- The Rebrand (July 2026): After months of internal development, the company officially retired the WTWH Media name in favor of Arrowfly, signaling a departure from its early roots toward a more cohesive, future-facing corporate identity.
Supporting Data: The Scope of Influence
The scale of the company—now operating as Arrowfly—is significant. By managing 40+ brands and 45+ events, the company acts as a central hub for professional B2B intelligence.
In the realm of life sciences, this influence is particularly pronounced. The integration of data-driven journalism and professional networking events creates a "closed loop" for industry professionals. Readers of Drug Discovery & Development do not just consume news; they interact with a community.
Furthermore, the company’s reliance on expert editorial staff—such as industry veterans who possess deep technical knowledge in AI, NLP, and predictive analytics—distinguishes the organization from generalist news outlets. By focusing on "Industry 4.0" and the integration of advanced technology into traditional pharmaceutical workflows, Arrowfly has ensured that its publications remain indispensable to researchers, executives, and policy-makers alike.
Official Perspectives: The Vision Behind the Name
In a statement addressing the rebrand, Arrowfly CEO Matt Logan emphasized that while the brand identity has evolved, the core mission remains immutable.
"We built this company by earning the trust of professionals in industries where editorial authority matters," Logan stated. "The name is new, but the foundation is the same: editors who speak each industry’s language, events that connect buyers and sellers who would never meet otherwise, and communities that professionals rely on for the insight and intelligence they need to make real decisions."
The choice of "Arrowfly" suggests a trajectory of forward motion, precision, and agility—qualities that the company claims are essential for navigating the rapidly changing landscape of global industry. It reflects a desire to move beyond the legacy of its founding initials and toward a brand that symbolizes the "flight" of information and the speed of modern business.
Implications for the Industry
The rebranding of a major B2B media player like Arrowfly carries several implications for the sectors it covers, particularly healthcare and drug development.
1. Enhanced Editorial Stability
By explicitly confirming that Drug Discovery & Development will remain unchanged, Arrowfly is signaling to its readers and advertisers that the value proposition of their media products is the primary focus. In an era of media consolidation where quality often suffers, this public commitment to the brand identity of its publications is a strategic move to maintain reader loyalty.
2. A Digital-First Strategy
The rebranding suggests that Arrowfly intends to lean further into digital intelligence. With a leadership team focused on data analysis, NLP, and AI-driven content distribution, the company is positioning itself to be more than just a publisher. It is evolving into a media-tech firm that leverages its massive database of industry interactions to provide predictive insights.
3. Increased Networking Synergies
With 45+ annual events, the Arrowfly network acts as a marketplace for innovation. By consolidating these under a unified corporate banner, the company is likely to increase the cross-pollination between its engineering and life science divisions. As drug development becomes increasingly reliant on complex medical devices, AI-assisted robotics, and advanced materials, the ability to draw expertise from across the entire Arrowfly portfolio becomes a competitive advantage.
4. Market Credibility and Investment
The backing of Mountaingate Capital, coupled with the hiring of a seasoned veteran like Matt Logan, suggests that Arrowfly is positioning itself for sustained growth. For investors and industry stakeholders, the move to a clean, modern brand name like Arrowfly indicates a company that is looking toward long-term institutional stability rather than short-term gains.
Conclusion: Looking Ahead
As the dust settles on the rebranding, the industry will be watching to see how Arrowfly executes its vision. The name "Arrowfly" evokes a sense of trajectory—a reminder that in the fast-paced world of drug discovery and life sciences, standing still is equivalent to moving backward.
For the readers of Drug Discovery & Development, the transition represents a promise: that the high-quality, rigorous, and expert-led journalism they have relied upon for years will not only continue but will be supported by a more robust, technologically advanced, and agile corporate parent.
As Matt Logan noted, the "foundation is the same." By honoring its roots while rebranding for the future, Arrowfly is positioning itself to remain the definitive voice in B2B media for years to come. For more information regarding the transition and the future of the company’s various platforms, stakeholders are encouraged to visit the official company website at arrowfly.com.
About the Editorial Focus
The transition to Arrowfly occurs at a time when the pharmaceutical and biotech industries are undergoing a massive technological shift. The editorial team, including industry experts like Brian Buntz, continues to prioritize coverage of transformative technologies. From the implementation of artificial intelligence and machine learning in early-stage discovery to the complexities of clinical trial data management and the integration of Industry 4.0 standards in manufacturing, the publications under the Arrowfly umbrella remain at the forefront of the conversation.
The commitment to deep-dive reporting—exploring topics from NLP clustering to predictive analytics—ensures that as the industry evolves, the intelligence provided by Arrowfly remains both relevant and actionable. This dedication to editorial excellence is the cornerstone upon which the new Arrowfly brand is built, ensuring that the legacy of WTWH Media continues to thrive under a new, unified identity.
About the Author
